Lantheus (NASDAQ:LNTH) Earns Buy Rating from Analysts at The Goldman Sachs Group

Investment analysts at The Goldman Sachs Group assumed coverage on shares of Lantheus (NASDAQ:LNTH) in a research note issued to investors on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $143.00 price target on the medical equipment provider’s stock. The Goldman Sachs Group’s price target would suggest a potential upside of 55.54% from the stock’s current price.

Several other brokerages have also recently commented on LNTH. Truist Financial restated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities decreased their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Price Performance

NASDAQ LNTH opened at $91.94 on Wednesday. The stock’s 50 day simple moving average is $96.63 and its 200 day simple moving average is $98.18. Lantheus has a one year low of $50.20 and a one year high of $126.89. The firm has a market cap of $6.39 billion, a PE ratio of 15.30 and a beta of 0.45.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus during the third quarter worth approximately $25,000. Signaturefd LLC raised its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares during the last quarter. UMB Bank n.a. raised its position in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus in the 3rd quarter valued at $51,000. Finally, GAMMA Investing LLC grew its stake in shares of Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.